Exact Mass: 274.9919
Exact Mass Matches: 274.9919
Found 183 metabolites which its exact mass value is equals to given mass value 274.9919,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
S-(4-Bromophenyl)-L-cysteine
S-(4-bromophenyl)-L-cysteine is a L-cysteine thioether and a bromoamino acid. It is a tautomer of a S-(4-bromophenyl)-L-cysteine zwitterion. S-(4-Bromophenyl)-L-cysteine is a natural product found in Euglena gracilis
D-glucosaminic acid 6-phosphate
ebselen
D018501 - Antirheumatic Agents > D000894 - Anti-Inflammatory Agents, Non-Steroidal > D016861 - Cyclooxygenase Inhibitors C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D018696 - Neuroprotective Agents D005765 - Gastrointestinal Agents > D000897 - Anti-Ulcer Agents D002491 - Central Nervous System Agents > D000700 - Analgesics C471 - Enzyme Inhibitor > C1323 - Cyclooxygenase Inhibitor D020011 - Protective Agents > D000975 - Antioxidants C26170 - Protective Agent > C275 - Antioxidant D000893 - Anti-Inflammatory Agents D004791 - Enzyme Inhibitors Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
N-(2-formyl-3-chlorophenyl)anthranilic acid
N-(2-formyl-3-chlorophenyl)anthranilic acid belongs to the family of Aminobenzoic Acid Derivatives. These are organic compounds containing a benzoic acid moiety with an amine group attached to the benzene ring.
Lorcaserin sulfamate
Lorcaserin sulfamate is a metabolite of lorcaserin. Lorcaserin (APD-356, trade name Lorqess) is a weight-loss drug developed by Arena Pharmaceuticals. It has serotonergic properties and acts as an anorectic. On 22 December 2009 a New Drug Application (NDA) was submitted to the Food and Drug Administration (FDA) in the United States. On 16 September 2010, an FDA advisory panel voted to recommend against approval of the drug based on concerns over both safety and efficacy. (Wikipedia)
Iobenguane
D019995 - Laboratory Chemicals > D007202 - Indicators and Reagents > D019275 - Radiopharmaceuticals D000970 - Antineoplastic Agents D004791 - Enzyme Inhibitors
Meticrane
C - Cardiovascular system > C03 - Diuretics > C03B - Low-ceiling diuretics, excl. thiazides > C03BA - Sulfonamides, plain C78275 - Agent Affecting Blood or Body Fluid > C448 - Diuretic > C49185 - Thiazide Diuretic
(5R)-3-Ethylsulfanyl-6-(1-hydroxyethyl)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
acetarsol
G - Genito urinary system and sex hormones > G01 - Gynecological antiinfectives and antiseptics > G01A - Antiinfectives and antiseptics, excl. combinations with corticosteroids > G01AB - Arsenic compounds P - Antiparasitic products, insecticides and repellents > P01 - Antiprotozoals > P01C - Agents against leishmaniasis and trypanosomiasis > P01CD - Arsenic compounds A - Alimentary tract and metabolism > A07 - Antidiarrheals, intestinal antiinflammatory/antiinfective agents > A07A - Intestinal antiinfectives C254 - Anti-Infective Agent > C276 - Antiparasitic Agent > C250 - Antihelminthic Agent D000890 - Anti-Infective Agents
7,8-Dihydroxy-3-(2-methyl-thiazol-4-yl)-chromen-4-one
4-CHLOROMETHYL-3-(2,6-DICHLOROPHENYL)-5-METHYLISOXAZOLE
(8-BENZYLOXY-IMIDAZO[1,2-A]PYRIDIN-2-YL)-ACETICACID
Ethyl2-amino-2-[2-(2,4-dichlorophenyl)hydrazono]-acetate
Methyl 5-bromo-2-hydroxy-3-nitrobenzenecarboxylate
PYRIDO[4,3:4,5]THIENO[2,3-D]PYRIMIDINE,4-CHLORO-5,6,7,8-TETRAHYDRO-7-METHYL-,MONOHYDROCHLORIDE
3-HYDROXYMETHYL-6-(2-NITROPHENYL)IMIDAZO[2,1-B]THIAZOLE
METHYL 2-METHYL-4-HYDROXY-2H-THIENO[2,3-E]-1,2-THIAZINE-3-CARBOXYLATE-1,1-DIOXIDE
10H-Pyridazino[6,1-b]quinazoline-2-carboxylic acid, 8-chloro-10-oxo-
4-chloro-1-(3-nitrophenyl)pyrazolo[3,4-d]pyrimidine
Methyl 4-hydroxy-2-methyl-2H-thieno[2,3-e][1,2]-thiazine-3-carboxylate 1,1-dioxide
4-chloro-7-(trifluoromethyl)quinoline-3-carboxylic acid
5-methyl-3-phenyl-2-sulfanylidene-4H-[1,3]thiazolo[4,5-d]pyrimidin-7-one
6-AMINO-5-BROMO-1-ISOBUTYL-3-METHYL-1H-PYRIMIDINE-2,4-DIONE
7-CHLORO-4-MERCAPTOQUINOLINE-2-CARBOXYLIC ACID HCL
2-(2-CHLORO-ACETYLAMINO)-4,5-DIMETHYL-THIOPHENE-3-CARBOXYLIC ACID ETHYL ESTER
Licostinel
D018377 - Neurotransmitter Agents > D018683 - Excitatory Amino Acid Agents > D018691 - Excitatory Amino Acid Antagonists C26170 - Protective Agent > C1509 - Neuroprotective Agent
4-(CHLOROMETHYL)-2-(4-METHOXYPHENYL)-1,3-THIAZOLE HYDROCHLORIDE
5-((2,4-DICHLOROPHENOXY)METHYL)-4H-1,2,4-TRIAZOLE-3-THIOL
4-Chloro-1-(4-nitrophenyl)-1H-pyrazolo[3,4-d]pyrimidine
2-(5-nitrothiophen-2-yl)-2,3-dihydro-1H-quinazolin-4-one
6-IODO-3-METHYL-1H-IMIDAZO[4,5-B]PYRIDIN-2(3H)-ONE
methyl 3-(pyrrolidin-1-ylsulfonyl)thiophene-2-carboxylate
4-chloro-6-(4-methylphenyl)-2-(methylthio)pyrimidine-5-carbonitrile
6-bromo-4-ethyl-1,2,3,4-tetrahydroisoquinoline,hydrochloride
Arsonic acid,As-[4-[(2-hydroxyacetyl)amino]phenyl]-
(4,5-dimethoxy-2-nitrophenyl)methyl carbonochloridate
4-(CHLOROMETHYL)-5-METHYL-2-(4-(TRIFLUOROMETHYL)PHENYL)OXAZOLE
Iobenguane I-131
V - Various > V10 - Therapeutic radiopharmaceuticals > V10X - Other therapeutic radiopharmaceuticals > V10XA - Iodine (131i) compounds D019995 - Laboratory Chemicals > D007202 - Indicators and Reagents > D019275 - Radiopharmaceuticals V - Various > V09 - Diagnostic radiopharmaceuticals > V09I - Tumour detection C1446 - Radiopharmaceutical Compound > C2124 - Radioconjugate D000970 - Antineoplastic Agents D004791 - Enzyme Inhibitors
6-BROMO-3,4-DIHYDRO-1H-S,S-DI-OXO-ISOTHIOCHROMEN-4-AMINE HYDROCHLORIDE
2-Chloromethyl-3-methyl-4-(2,2,2-trifluoroethoxy)pyridine hydrochloride
Cyclobutanemethanamine, 1-(4-bromophenyl)-, hydrochloride (1:1)
4-(chloromethyl)-2-(3-methoxyphenyl)-1,3-thiazole hydrochloride
3-piperidin-1-ylsulfonylthiophene-2-carboxylic acid
4-ACETYL-3,4-DIHYDRO-2H-BENZO[B][1,4]OXAZINE-6-SULFONYL CHLORIDE
1-Benzyl-4-bromo-5-methyl-1H-pyrazole-3-carbonitrile
1-Benzyl-4-bromo-3-methyl-1H-pyrazole-5-carbonitrile
5-(2-Chlorophenyl)-1,3,4-thiadiazole-2-sulfonamide
Iobenguane I-123
V - Various > V09 - Diagnostic radiopharmaceuticals > V09I - Tumour detection C1446 - Radiopharmaceutical Compound > C2124 - Radioconjugate
5-{[(2-Chloro-6-fluorophenyl)methyl]sulfanyl}-1,3,4-thiadiazol-2-amine
N-(3,4-dichlorophenyl)-N-[(dimethylamino)methylene]thiourea
2-[(3-chlorophenyl)methylsulfanyl]-3H-imidazo[4,5-c]pyridine
(2,4-Dichloro-5-hydroxyphenyl) pyrrolidine-1-carboxylate
4-Amino-N-[(2-Sulfanylethyl)carbamoyl]benzenesulfonamide
Meticrane
C - Cardiovascular system > C03 - Diuretics > C03B - Low-ceiling diuretics, excl. thiazides > C03BA - Sulfonamides, plain C78275 - Agent Affecting Blood or Body Fluid > C448 - Diuretic > C49185 - Thiazide Diuretic
5,7-Dimethyl-3-methylsulfonyl-[1,2]thiazolo[3,4-d]pyrimidine-4,6-dione
Lorcaserin sulfamate
Lorcaserin sulfamate is a metabolite of lorcaserin. Lorcaserin (APD-356, trade name Lorqess) is a weight-loss drug developed by Arena Pharmaceuticals. It has serotonergic properties and acts as an anorectic. On 22 December 2009 a New Drug Application (NDA) was submitted to the Food and Drug Administration (FDA) in the United States. On 16 September 2010, an FDA advisory panel voted to recommend against approval of the drug based on concerns over both safety and efficacy. (Wikipedia)
(5-Methylsulfinylpentanethioylamino) hydrogen sulfate
3-Ethylsulfanyl-6-(1-hydroxyethyl)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
acetic acid [3-oxo-2-(trifluoromethyl)-4H-1,4-benzoxazin-2-yl] ester
2-[[5-(2-furanyl)-1,3,4-oxadiazol-2-yl]thio]-1-(1H-pyrrol-2-yl)ethanone
Sodium;(4-aminophenyl)sulfonyl-(4-methyl-1,2-oxazol-3-yl)azanide
Iobenguane
D019995 - Laboratory Chemicals > D007202 - Indicators and Reagents > D019275 - Radiopharmaceuticals D000970 - Antineoplastic Agents D004791 - Enzyme Inhibitors
6-Phospho-D-gluconate
A monocarboxylic acid anion resulting from the removal of a proton from the carboxy group of 6-phospho-D-gluconic acid.
